Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18-65 years of age~* Chronic hepatitis C genotype 1~* HCV treatment naïve, or without sustained virologic response on prior PEG-INF/RBV treatment~* Body mass index (BMI) 18 - 35 kg/m2, inclusive; minimum weight 45 kg~Exclusion Criteria:~* Liver cirrhosis~* Decompensated liver disease or impaired liver function~* Medical condition associated with chronic liver disease other than chronic hepatitis C~* Positive for hepatitis B or HIV infection at screening~* History of alcohol consumption exceeding 2 standard drinks per day when averaged over the course of a given week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: EXPERIMENTAL): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).